Status:
ACTIVE_NOT_RECRUITING
Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring
Lead Sponsor:
Qianfoshan Hospital
Conditions:
AKI
Therapeutic Drug Monitoring (TDM)
Eligibility:
All Genders
18+ years
Brief Summary
In this study, the investigators will focus on hospitalized patients using cyclosporine and develop an acute kidney injury risk prediction model through in-depth analysis of electronic medical record ...
Eligibility Criteria
Inclusion
- During hospitalization, tacrolimus or cyclosporine was used, and therapeutic drug monitoring was conducted according to standard procedures.
- Aged 18 years or older at the time of admission.
- Length of hospital stay \> 48 hours.
- At least 2 serum creatinine tests were conducted during hospitalization.
Exclusion
- Chronic kidney disease stage 5 was achieved before admission.
- Incomplete clinical data.
- Serum creatinine levels were consistently below 40 mmol/L during hospitalization.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06596811
Start Date
September 1 2024
End Date
December 30 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, China, 250117